Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Top Cited Papers
- 5 February 2009
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 360 (6), 573-587
- https://doi.org/10.1056/nejmoa0807684
Abstract
Following the release of the 2002 report of the Women's Health Initiative (WHI) trial of estrogen plus progestin, the use of menopausal hormone therapy in the United States decreased substantially. Subsequently, the incidence of breast cancer also dropped, suggesting a cause-and-effect relation between hormone treatment and breast cancer. However, the cause of this decrease remains controversial. We analyzed the results of the WHI randomized clinical trial — in which one study group received 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate daily and another group received placebo — and examined temporal trends in breast-cancer diagnoses in the WHI observational-study cohort. Risk factors for breast cancer, frequency of mammography, and time-specific incidence of breast cancer were assessed in relation to combined hormone use. In the clinical trial, there were fewer breast-cancer diagnoses in the group receiving estrogen plus progestin than in the placebo group in the initial 2 years of the study, but the number of diagnoses increased over the course of the 5.6-year intervention period. The elevated risk decreased rapidly after both groups stopped taking the study pills, despite a similar frequency of mammography. In the observational study, the incidence of breast cancer was initially about two times as high in the group receiving menopausal hormones as in the placebo group, but this difference in incidence decreased rapidly in about 2 years, coinciding with year-to-year reductions in combined hormone use. During this period, differences in the frequency of mammography between the two groups were unchanged. The increased risk of breast cancer associated with the use of estrogen plus progestin declined markedly soon after discontinuation of combined hormone therapy and was unrelated to changes in frequency of mammography.This publication has 33 references indexed in Scilit:
- Estrogen Plus Progestin Therapy and Breast Cancer in Recently Postmenopausal WomenAmerican Journal of Epidemiology, 2008
- Regional Changes in Hormone Therapy Use and Breast Cancer Incidence in California From 2001 to 2004Journal of Clinical Oncology, 2007
- Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. womenBreast Cancer Research, 2007
- Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapyBreast Cancer Research and Treatment, 2007
- Hereditary breast cancer growth rates and its impact on screening policyEuropean Journal of Cancer, 2005
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJama-Journal Of The American Medical Association, 2002
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJama-Journal Of The American Medical Association, 1998
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994
- Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined AnnuallyJNCI Journal of the National Cancer Institute, 1989